Effimune S.A.S. is a biotechnology company conducting research and development of innovative drug candidates for transplantation and immune-mediated diseases. The company specializes in the development of first-in-class biological drug candidates targeting cells of the immune system to restore the balance between effector and regulatory mechanisms. Three product candidates are currently in development, one of them in collaboration with our partners Janssen Biotech.